 |
16 Products |  |
56 Diseases | | 16 Products |
|
38 Trials |  |
954 News |  |
| 12345678910111213...1314» |
- | ASP7317 / Octapharma, Astellas
Trial completion date, Trial primary completion date: A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration (clinicaltrials.gov) - Nov 18, 2024
P1, N=42, Recruiting, Sponsor: Astellas Institute for Regenerative Medicine
Trial completion date: Jan 2026 --> Jun 2026 | Trial primary completion date: Jan 2026 --> Jun 2026
- Nuwiq (simoctocog alfa) / Octapharma, IDO 8 / Idogen
Role of Factor VIII in Angiogenesis, Vessel Stability and the Regulation of Extracellular Matrix Proteins (Halls G-H (San Diego Convention Center)) - Nov 6, 2024 - Abstract #ASH2024ASH_6888;
Trial completion date: Jan 2026 --> Jun 2026 | Trial primary completion date: Jan 2026 --> Jun 2026 Hemophilia A (HA) is a rare X-linked disorder leading to deficient or dysfunctional FVIII resulting in impaired hemostasis...Recombinant (r)FVIII (Nuwiq
- Rapido: Results from a UK-Wide Audit of 2477 Patients Who Received a Reversal Agent for a Direct Oral Anticoagulant (Halls G-H (San Diego Convention Center)) - Nov 6, 2024 - Abstract #ASH2024ASH_6799;
Further, detailed analysis of this rich dataset is on-going, and a propensity score-matched analysis of patients with GI hemorrhage will be performed to compare outcomes in patients treated with andexanet alfa, Beriplex and Octaplex. Funding This project was conducted with support from AstraZeneca UK Limited.
- Fibryga (fibrinogen concentrate (human)) / Octapharma
Title: Real-World Utilization of Human Fibrinogen Concentrate in Managing Bleeding in Adult and Pediatric Patients: A Retrospective Study (Halls G-H (San Diego Convention Center)) - Nov 6, 2024 - Abstract #ASH2024ASH_6308;
The existing findings provide justification for the adoption of human fibrinogen concentrate in many clinical scenarios, including both surgical and nonsurgical hemorrhage. The practical benefits and predictable effects of human fibrinogen concentrate in place of standard treatments highlight its potential to not only enhance patient outcomes but also provide for optimized clinical workflows.
- Nuwiq (simoctocog alfa) / Octapharma
Indirect Comparison of the Efficacy and Therapy-Related Costs of a Pharmacokinetic and Individualized Prophylaxis Regimen with Simoctocog Alfa Versus Other Extended-Half Life Factor VIII Concentrates (Halls G-H (San Diego Convention Center)) - Nov 6, 2024 - Abstract #ASH2024ASH_4703;
The practical benefits and predictable effects of human fibrinogen concentrate in place of standard treatments highlight its potential to not only enhance patient outcomes but also provide for optimized clinical workflows. For comparison, aggregated data was obtained from the following trials with EHL concentrates: pathfinder2 (turoctocog alfa pegol, N = 175), A-LONG (efmoroctocog alfa, N = 117), PROTECT FVIII (damoctocog alfa pegol, N = 110), PROPEL (rurioctocog alfa pegol 1
- Wilate (human factor VIII/von Willebrand factor) / Octapharma
Efficacy and Safety of Prophylaxis with a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate Among Von Willebrand Disease Patients across All ABO Antigen Blood Groups (Halls G-H (San Diego Convention Center)) - Nov 6, 2024 - Abstract #ASH2024ASH_4149;
P, P3
For comparison, aggregated data was obtained from the following trials with EHL concentrates: pathfinder2 (turoctocog alfa pegol, N = 175), A-LONG (efmoroctocog alfa, N = 117), PROTECT FVIII (damoctocog alfa pegol, N = 110), PROPEL (rurioctocog alfa pegol 1 wilate
- Disparities in Real-World Treatment Patterns Among Patients with Von Willebrand Disease in a Large US Population-Based Dataset (Halls G-H (San Diego Convention Center)) - Nov 6, 2024 - Abstract #ASH2024ASH_4142;
The bleeding phenotypes and hemostatic medications used to treat VWD patients are variable. Even in recent years, prophylactic treatment has been used in a minority of VWD patients who have bleeding comorbidities, despite some experiencing severe and frequent bleeds.
- Role of Factor VIII As a Regulator of Angiogenesis and Promoter of Endothelial Barrier Stability (Halls G-H (San Diego Convention Center)) - Nov 6, 2024 - Abstract #ASH2024ASH_4113;
Even in recent years, prophylactic treatment has been used in a minority of VWD patients who have bleeding comorbidities, despite some experiencing severe and frequent bleeds. HA BOECs were treated in vitro with the rFVIII products simoctocog alfa (Nuwiq
- ||||| Panzyga (immune globulin intravenous, human-ifas) / Octapharma, Pfizer
Trial completion, Head-to-Head: NGAM-13: Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS) (clinicaltrials.gov) - Nov 4, 2024
P3, N=71, Completed, Sponsor: Octapharma
HA BOECs were treated in vitro with the rFVIII products simoctocog alfa (Nuwiq Active, not recruiting --> Completed
- Wilate (human factor VIII/von Willebrand factor) / Octapharma, Biostate (factor VIII/von Willebrand factor) / CSL Behring, Vonvendi (vonicog alfa) / Takeda
Leveraging National Real-World Evidence to Understand Differences of Economic Burden in Rare Diseases: The Case of Von Willebrand Disease in France () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_674;
Active, not recruiting --> Completed Within adult on-demand users, HRUC related to hospitalizations, in-hospital RT and FVIII, outpatient general practitioner and nurse visits, out-hospital RT and FVIII dispensings were assessed by AP and compared across RTs (Wilfactin
- | Atenativ (human antithrombin III) / Octapharma
Trial completion date, Trial primary completion date, Surgery: ATN-106: Efficacy of Atenativ in Patients with Congenital Antithrombin Deficiency Undergoing Surgery or Delivery (clinicaltrials.gov) - Nov 3, 2024
P3, N=38, Recruiting, Sponsor: Octapharma
Within adult on-demand users, HRUC related to hospitalizations, in-hospital RT and FVIII, outpatient general practitioner and nurse visits, out-hospital RT and FVIII dispensings were assessed by AP and compared across RTs (Wilfactin Trial completion date: Jun 2025 --> Dec 2025 | Trial primary completion date: Jun 2025 --> Dec 2025
- Fibryga (fibrinogen concentrate (human)) / Octapharma
SY105. Beyond the Bleed: Revolutionizing Precision in Hemorrhage Management (non-CME) (120B) - Oct 19, 2024 - Abstract #ASA2024ASA_6856;
Propel your bleeding management practice to new heights! Octapharma, Annual Meeting Supporter
- | Octagam (intravenous normal human immunoglobulin) / Octapharma, Pfizer
Journal: IVIG response in pediatric acute-onset neuropsychiatric syndrome correlates with reduction in pro-inflammatory monocytes and neuropsychiatric measures. (Pubmed Central) - Oct 18, 2024
Children with moderate-to-severe PANS received six infusions of IVIG (Octagam 5%, Octapharma) every 3 weeks with post treatment follow-up...This pro-inflammatory profile and psychometric scores improved following IVIG treatment. Future work will aim to further elucidate the roles of innate and adaptive immune responses in PANS and the regulatory mechanism(s) of IVIG in PANS treatment.
- Fibryga (fibrinogen concentrate (human)) / Octapharma
Cancelled: A Real-World, Retrospective, Observational Study of Fibrinogen Concentrate in Patients With Acute Gastrointestinal Hemorrhage and Fibrinogen Deficiency: Sub-Analysis of the FORMA-10 Study () - Oct 8, 2024 - Abstract #AABB2024AABB_330;
P=N/A
This real-world data shows that FC was successful for on-demand treatment of non?surgical GI bleeding, with a favorable safety profile. These findings provide valuable insights to aid clinicians in making informed decisions regarding the use of FC for the management of GI bleeding.
- ||||| Panzyga (immune globulin intravenous, human-ifas) / Octapharma, Pfizer
Enrollment closed: PROSID: Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study) (clinicaltrials.gov) - Oct 1, 2024
P3, N=240, Active, not recruiting, Sponsor: Octapharma
These findings provide valuable insights to aid clinicians in making informed decisions regarding the use of FC for the management of GI bleeding. Recruiting --> Active, not recruiting
- Octagam (intravenous normal human immunoglobulin) / Octapharma, Pfizer
Efficacy of Intravenous Immunoglobulin (Octagam 10%) on Pulmonary Manifestations in Patients with Dermatomyositis: Results from the ProDERM Study (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2820;
IVIg may have favorable treatment effects on active pulmonary manifestations of DM. Further studies are warranted.
- | Wilate (human factor VIII/von Willebrand factor) / Octapharma
Journal: Haemostatic management of von Willebrand disease during childbirth with a plasma-derived VWF/FVIII concentrate. (Pubmed Central) - Sep 21, 2024
Further studies are warranted. The results of this case series indicate that wilate provided effective hemostatic cover for childbirth in females with VWD during delivery and postpartum.
- |||| Wilate (human factor VIII/von Willebrand factor) / Octapharma
Trial completion date, Trial primary completion date: Von Willebrand Factor in Pregnancy (VIP) Study (clinicaltrials.gov) - Sep 19, 2024
P=N/A, N=110, Recruiting, Sponsor: University of Washington
The results of this case series indicate that wilate provided effective hemostatic cover for childbirth in females with VWD during delivery and postpartum. Trial completion date: Jun 2023 --> Dec 2026 | Trial primary completion date: Jun 2023 --> Dec 2026
- | Hemlibra (emicizumab-kxwh) / Roche, Nuwiq (simoctocog alfa) / Octapharma
Journal: Deciphering the circulating microRNA signature of hemophilic arthropathy. (Pubmed Central) - Aug 26, 2024
These miRNAs are potential negative regulators of gene expression, suggesting their activity in HArt by interfering with osteoblastic (miR- 208a-3p) and osteoclastic (miR-506-3p) differentiation to impair bone mineralization and remodeling processes, or regulating chondrogenesis (miR-335-5p). miRNAs associated with earlier stages of HArt will be further investigated in a sub-study of the prospective clinical trial PROVE, which will investigate the effects of long-term prophylaxis with simoctocog alfa versus emicizumab in adults with hemophilia A.
- ||| Octaplex (human prothrombin complex concentrate) / Octapharma, Pfizer
Clinical protocol, P3 data, Journal, Surgery: Protocol for a phase 3, randomised, active-control study of four-factor prothrombin complex concentrate versus frozen plasma in bleeding adult cardiac surgery patients requiring coagulation factor replacement: the LEX-211 (FARES-II) trial. (Pubmed Central) - Aug 23, 2024
P3
The primary objective is to determine whether 4F-PCC (Octaplex/Balfaxar, Octapharma) is clinically non-inferior to FP for haemostatic effectiveness...The results will advance our understanding of coagulation management in bleeding surgical patients, potentially reducing the need for allogeneic blood products and improving outcomes in surgical patients. NCT05523297.
- ||||| Wilate (human factor VIII/von Willebrand factor) / Octapharma, Nuwiq (simoctocog alfa) / Octapharma
Enrollment change: PREVAIL: Immune Tolerance Induction in Haemophilia A Patients Using Wilate or Nuwiq (clinicaltrials.gov) - Aug 9, 2024
P=N/A, N=14, Terminated, Sponsor: Octapharma
NCT05523297. N=80 --> 14
- | Panzyga (immune globulin intravenous, human-ifas) / Octapharma, Pfizer
Enrollment change, Trial termination, Trial primary completion date: Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP) (clinicaltrials.gov) - Aug 7, 2024
P4, N=6, Terminated, Sponsor: Octapharma
N=80 --> 14 N=20 --> 6 | Active, not recruiting --> Terminated | Trial primary completion date: Apr 2024 --> Sep 2023; FDA released Octapharma from the pediatric post marketing requirement.
- Nuwiq (simoctocog alfa) / Octapharma
Enrollment open, Surgery: Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery (clinicaltrials.gov) - Jul 22, 2024
P4, N=28, Recruiting, Sponsor: Octapharma
N=20 --> 6 | Active, not recruiting --> Terminated | Trial primary completion date: Apr 2024 --> Sep 2023; FDA released Octapharma from the pediatric post marketing requirement. Not yet recruiting --> Recruiting
- ||||||| Balfaxar (prothrombin complex concentrate, human-lans) / Octapharma, Pfizer
Trial completion, Surgery: FARES-2: Active-control Randomised Trial Comparing 4-factor Prothrombin Complex Concentrate With Frozen Plasma in Cardiac Surgery (clinicaltrials.gov) - Jul 10, 2024
P3, N=419, Completed, Sponsor: Octapharma
Not yet recruiting --> Recruiting Recruiting --> Completed
- |||| Gammanorm (human immune globulin subcutaneous) / Octapharma
Trial completion date, Trial primary completion date: Observational Study of Subcutaneous Immunoglobulin (Cutaquig) in Patients with Primary and Secondary Immunodeficiency. (clinicaltrials.gov) - Jul 9, 2024
P=N/A, N=30, Recruiting, Sponsor: University of Alberta
Recruiting --> Completed Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Jun 2024 --> Dec 2024
- ||| Panzyga (immune globulin intravenous, human-ifas) / Octapharma, Pfizer
Trial completion date, Trial primary completion date, Head-to-Head: NGAM-13: Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS) (clinicaltrials.gov) - Jul 4, 2024
P3, N=71, Active, not recruiting, Sponsor: Octapharma
Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Jun 2024 --> Dec 2024 Trial completion date: Jun 2024 --> Oct 2024 | Trial primary completion date: Jun 2024 --> Oct 2024
- |||| Panzyga (immune globulin intravenous, human-ifas) / Octapharma, Pfizer
Enrollment closed, Head-to-Head: NGAM-13: Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS) (clinicaltrials.gov) - Jun 17, 2024
P3, N=70, Active, not recruiting, Sponsor: Octapharma
Trial completion date: Jun 2024 --> Oct 2024 | Trial primary completion date: Jun 2024 --> Oct 2024 Terminated --> Active, not recruiting
- | Fibryga (fibrinogen concentrate (human)) / Octapharma
Journal: Are all fibrinogen concentrates the same? The effects of two fibrinogen therapies in an afibrinogenemic patient and in a fibrinogen deficient plasma model. A clinical and laboratory case report. (Pubmed Central) - Jun 14, 2024
Our report offers insights into the differential effects of these concentrates, at the clot level, according to the variable constituents of each product, thereby emphasizing that the choice of fibrinogen concentrate can influence the stability of a clot in vivo. Whether this alters clinical efficacy is yet to be understood.
- ||||||| Panzyga (immune globulin intravenous, human-ifas) / Octapharma, Pfizer
Trial completion date, Trial termination, Trial primary completion date, Head-to-Head: NGAM-13: Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS) (clinicaltrials.gov) - Jun 9, 2024
P3, N=70, Terminated, Sponsor: Octapharma
Whether this alters clinical efficacy is yet to be understood. Trial completion date: Oct 2024 --> May 2024 | Recruiting --> Terminated | Trial primary completion date: Oct 2024 --> May 2024
- |||||| Balfaxar (prothrombin complex concentrate, human-lans) / Octapharma, Pfizer
New trial, Surgery: Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure (clinicaltrials.gov) - May 28, 2024
P=N/A, N=3574, Not yet recruiting, Sponsor: Octapharma
- Wilate (human factor VIII/von Willebrand factor) / Octapharma
Efficacy and Safety of Prophylaxis with a Plasma-derived von Willebrand Factor/Factor VIII Concentrate in Type 3 Patients with von Willebrand Disease (Ballroom B4) - May 17, 2024 - Abstract #ISTH2024ISTH_2212;
P3
Trial completion date: Oct 2024 --> May 2024 | Recruiting --> Terminated | Trial primary completion date: Oct 2024 --> May 2024 Background: The WIL-31 study (NCT04052698) demonstrated the efficacy and safety of regular prophylaxis with a plasma-derived von Willebrand factor/factor VIII concentrate (pdVWF/FVIII; wilate
- Wilate (human factor VIII/von Willebrand factor) / Octapharma
Bleeding Sites in von Willebrand Disease Patients on Prophylaxis with a Plasma-derived von Willebrand Factor/Factor VIII Concentrate (Ballroom B3) - May 17, 2024 - Abstract #ISTH2024ISTH_2162;
P3
Background: The WIL-31 study (NCT04052698) demonstrated the efficacy and safety of regular prophylaxis with a plasma-derived von Willebrand factor/factor VIII concentrate (pdVWF/FVIII; wilate Background: The WIL-31 study (NCT04052698) demonstrated the efficacy and safety of prophylaxis with a plasma-derived von Willebrand factor/factor VIII concentrate (pdVWF/FVIII; wilate
- Factor VIII is a regulator of angiogenesis and a promoter of endothelial barrier stability (111 A-C) - May 17, 2024 - Abstract #ISTH2024ISTH_2032;
A significant enhancement of EC functionality was demonstrated by treating HA BOECs with rFVIII products, with a higher positive effect for simoctocog alfa. Moreover, in NSG-HA mice treated with different rFVIII concentrates, and subsequently injected with Evans Blue dye, we showed a significant reduction of dye extravasation with a complete correction in mice treated with simoctocog alfa compared with other rFVIII products.
- Hemlibra (emicizumab-kxwh) / Roche, Nuwiq (simoctocog alfa) / Octapharma
miRNA expression profiles as a potential biomarker of joint and bone health in haemophilia A (111 A-C) - May 17, 2024 - Abstract #ISTH2024ISTH_2031;
The validation study evaluated these 2 miRNAs. The results demonstrated that two miRNAs (miR- 208a-3p and 524-3p) were significantly underexpressed in plasma of patients with HArt compared to patients without arthropathy, with FDR < 0.05 (Figure 1).
- Nuwiq (simoctocog alfa) / Octapharma
Impact of differential binding of recombinant factor VIII concentrates to platelets on platelet clotting functionality (210 A-D) - May 17, 2024 - Abstract #ISTH2024ISTH_1987;
Through a time-course analysis, we found that rFVIII interaction occurs already in proaggregatory platelets. This early interaction upregulates the intracellular signalling cascade leading to an increased shift from proaggregatory to procoagulant phenotype.
- Octaplex (human prothrombin complex concentrate) / Octapharma, Pfizer
Prothrombin complex concentrate for prophylaxis in a patient with Factor II deficiency, a case report (Exhibition Hall) - May 17, 2024 - Abstract #ISTH2024ISTH_1266;
This early interaction upregulates the intracellular signalling cascade leading to an increased shift from proaggregatory to procoagulant phenotype. We initiated prothrombin complex concentrate (Octaplex
- Hemlibra (emicizumab-kxwh) / Roche
Successful Management of Recurrent Ankle Hemarthrosis in a Patient with Von Willebrand Disease Type 3 using Emicizumab: A Case Report (Exhibition Hall) - May 17, 2024 - Abstract #ISTH2024ISTH_962;
Recurrent mucocutaneous bleeds, hemarthrosis, and a right ankle target joint significantly impacted the patient's quality of life. Genetic analysis confirmed a homozygous insertion mutation in the VWF gene.
- Altuviiio (antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl) / SOBI, Sanofi, Nuwiq (simoctocog alfa) / Octapharma
Indirect comparison of prophylaxis efficacy between simoctocog alfa and efanesoctocog alfa in severe hemophilia A and their cost in the United States (Exhibition Hall) - May 17, 2024 - Abstract #ISTH2024ISTH_928;
The mean weekly dose was significantly higher in patients treated with simoctocog alfa versus efanesoctocog alfa (98.3 IU/kg vs 52.2 IU/kg; p< 0.001). The median dosing interval in the NuPreviq study was 3.5 days; patients in the XTEND-1 study were treated once-weekly.
- Octagam (intravenous normal human immunoglobulin) / Octapharma
EFFICACY IN INFECTION PROPHYLAXIS AND SAFETY OF INTRAVENOUS IMMUNOGLOBULINS IN PATIENTS WITH HYPOGAMMAGLOBULINEMIA DUE TO HEMATOLOGICAL MALIGNANCIES: RESULTS FROM A NON-INTERVENTIONAL STUDY (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_4037;
The median dosing interval in the NuPreviq study was 3.5 days; patients in the XTEND-1 study were treated once-weekly. Both 5% and 10% IVIG-preparations were effective in reducing the frequency of infections and well tolerated inpatients with SID resulting from hematological malignancies and those treated with rituximab, with a favorablesafety profile.
- Octaplex (human prothrombin complex concentrate) / Octapharma, Pfizer
PROTHROMBIN COMPLEX CONCENTRATE USAGE IN UNIVERSITY COLLEGE LONDON HOSPITALS, A RETROSPECTIVE AUDIT (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_3347;
Both 5% and 10% IVIG-preparations were effective in reducing the frequency of infections and well tolerated inpatients with SID resulting from hematological malignancies and those treated with rituximab, with a favorablesafety profile. Aims: -Assessment of the use of PCC Prothrombin Complex Concentrate (Octaplex
- || Nuwiq (simoctocog alfa) / Octapharma
Review, Journal: Simoctocog alfa (Nuwiq (Pubmed Central) - May 13, 2024
Optimal care of children should consider several factors, including minimization of inhibitor development risk, maintaining tolerance to FVIII, highly effective bleed prevention and treatment, safety, and impact on long-term outcomes such as bone and joint health. In this context we review the pediatric clinical data and ongoing studies with simoctocog alfa.
- | Wilate (human factor VIII/von Willebrand factor) / Octapharma
Trial initiation date: EMPOWER: A Pilot Crossover Trial of Prophylactic Wilate Compared to Placebo for Heavy Menstrual Bleeding in Patients With VWD (clinicaltrials.gov) - May 8, 2024
P3, N=20, Not yet recruiting, Sponsor: Unity Health Toronto
In this context we review the pediatric clinical data and ongoing studies with simoctocog alfa. Initiation date: Jan 2024 --> Jun 2024
- | Atenativ (human antithrombin III) / Octapharma
Trial completion date, Trial primary completion date, Surgery: ATN-106: Efficacy of Atenativ in Patients with Congenital Antithrombin Deficiency Undergoing Surgery or Delivery (clinicaltrials.gov) - Apr 29, 2024
P3, N=38, Recruiting, Sponsor: Octapharma
Initiation date: Jan 2024 --> Jun 2024 Trial completion date: Dec 2024 --> Jun 2025 | Trial primary completion date: Dec 2024 --> Jun 2025
- Octagam (intravenous normal human immunoglobulin) / Octapharma
The many faces of primary immune deficiency in childhood (Poster Zone) - Apr 21, 2024 - Abstract #EAACI2024EAACI_2542;
Replacement therapy with human immunoglobulin (Octagam 10%) and isoprinosine was started at the age of 5 years and 4 months...The identification of defects in specific molecules or molecular signaling pathways has led to opportunities to apply targeted treatments that have proven particularly effective in controlling disease and improving health. ?ey words: immune deficiency, immune dysregulation, lymphoma, replacement therapy
- Octagam (intravenous normal human immunoglobulin) / Octapharma
Unveiling the Connection Between ?-Gal Allergy and Cardiovascular Disease (Cordoba) - Apr 5, 2024 - Abstract #EAACI2024EAACI_554;
?ey words: immune deficiency, immune dysregulation, lymphoma, replacement therapy Method For this, anti-?-Gal IgG antibodies were purified from a commercial intravenous human IgG concentrate (Octagam
- Kcentra (plasma-derived prothrombin complex concentrate) / CSL Behring, Octaplex (human prothrombin complex concentrate) / Octapharma, Pfizer
An investigational four-factor prothrombin complex concentrate for vitamin k antagonist reversal: hemostatic efficacy and safety demonstrated with and without concurrent vitamin k therapy () - Mar 18, 2024 - Abstract #ISICEM2024ISICEM_1008;
Method For this, anti-?-Gal IgG antibodies were purified from a commercial intravenous human IgG concentrate (Octagam LEX -209 was a Phase 3 non -inferiority randomized control trial of an investigational 4F -PCC (Octaplex
- Fibryga (fibrinogen concentrate (human)) / Octapharma
Forma-10 sub-analysis: a real-world, retrospective, observational study of fibrinogen concentrate in patients with trauma-related bleeding and fibrinogen deficiency () - Mar 18, 2024 - Abstract #ISICEM2024ISICEM_1007;
LEX -209 was a Phase 3 non -inferiority randomized control trial of an investigational 4F -PCC (Octaplex This contemporary, real -life data set indicates that fibrinogen concentrate is successfully used in the management of non -surgical trauma -related bleeding in a European healthcare setting.
- Octagam (intravenous normal human immunoglobulin) / Octapharma
Evaluation of Autoantibody Status Effect on Dermatomyositis Patients' Response to IVIG Treatment: Post-hoc Analysis of the ProDERM Trial (Colorado Convention Center | Exhibit Hall B-E) - Mar 8, 2024 - Abstract #AAN2024AAN_2863;
This contemporary, real -life data set indicates that fibrinogen concentrate is successfully used in the management of non -surgical trauma -related bleeding in a European healthcare setting. IVIg appears to be an effective agent for treatment of dermatomyositis, regardless of autoantibody status of the patient.
- |||| Panzyga (immune globulin intravenous, human-ifas) / Octapharma, Pfizer
Trial completion date, Trial primary completion date: PROSID: Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study) (clinicaltrials.gov) - Mar 6, 2024
P3, N=240, Recruiting, Sponsor: Octapharma
IVIg appears to be an effective agent for treatment of dermatomyositis, regardless of autoantibody status of the patient. Trial completion date: Oct 2024 --> Aug 2025 | Trial primary completion date: Oct 2024 --> Aug 2025
- | warfarin / Generic mfg.
Journal: Balfaxar: Another four-factor PCC for warfarin reversal. (Pubmed Central) - Mar 2, 2024
Trial completion date: Oct 2024 --> Aug 2025 | Trial primary completion date: Oct 2024 --> Aug 2025 No abstract available